Nirmatrelvir-resistant SARS-CoV-2 is efficiently transmitted in female Syrian hamsters and retains partial susceptibility to treatment
Abstract The SARS-CoV-2 main protease (3CLpro) is one of the promising therapeutic targets for the treatment of COVID-19. Nirmatrelvir is the first 3CLpro inhibitor authorized for treatment of COVID-19 patients at high risk of hospitalization. We recently reported on the in vitro selection of SARS-C...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2023-04-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-023-37773-6 |
| _version_ | 1797845872370778112 |
|---|---|
| author | Rana Abdelnabi Dirk Jochmans Kim Donckers Bettina Trüeb Nadine Ebert Birgit Weynand Volker Thiel Johan Neyts |
| author_facet | Rana Abdelnabi Dirk Jochmans Kim Donckers Bettina Trüeb Nadine Ebert Birgit Weynand Volker Thiel Johan Neyts |
| author_sort | Rana Abdelnabi |
| collection | DOAJ |
| description | Abstract The SARS-CoV-2 main protease (3CLpro) is one of the promising therapeutic targets for the treatment of COVID-19. Nirmatrelvir is the first 3CLpro inhibitor authorized for treatment of COVID-19 patients at high risk of hospitalization. We recently reported on the in vitro selection of SARS-CoV-2 3CLpro resistant virus (L50F-E166A-L167F; 3CLprores) that is cross-resistant with nirmatrelvir and other 3CLpro inhibitors. Here, we demonstrate that the 3CLprores virus replicates efficiently in the lungs of intranasally infected female Syrian hamsters and causes lung pathology comparable to that caused by the WT virus. Moreover, hamsters infected with 3CLprores virus transmit the virus efficiently to co-housed non-infected contact hamsters. Importantly, at a dose of 200 mg/kg (BID) of nirmatrelvir, the compound was still able to reduce the lung infectious virus titers of 3CLprores-infected hamsters by 1.4 log10 with a modest improvement in the lung histopathology as compared to the vehicle control. Fortunately, resistance to Nirmatrelvir does not readily develop in clinical setting. Yet, as we demonstrate, in case drug-resistant viruses emerge, they may spread easily which may thus impact therapeutic options. Therefore, the use of 3CLpro inhibitors in combination with other drugs may be considered, especially in immunodeficient patients, to avoid the development of drug-resistant viruses. |
| first_indexed | 2024-04-09T17:46:01Z |
| format | Article |
| id | doaj.art-5b37fc19f66e4452a1148cda697b09dd |
| institution | Directory Open Access Journal |
| issn | 2041-1723 |
| language | English |
| last_indexed | 2024-04-09T17:46:01Z |
| publishDate | 2023-04-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Nature Communications |
| spelling | doaj.art-5b37fc19f66e4452a1148cda697b09dd2023-04-16T11:19:48ZengNature PortfolioNature Communications2041-17232023-04-011411710.1038/s41467-023-37773-6Nirmatrelvir-resistant SARS-CoV-2 is efficiently transmitted in female Syrian hamsters and retains partial susceptibility to treatmentRana Abdelnabi0Dirk Jochmans1Kim Donckers2Bettina Trüeb3Nadine Ebert4Birgit Weynand5Volker Thiel6Johan Neyts7KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and ChemotherapyKU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and ChemotherapyKU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and ChemotherapyInstitute of Virology and Immunology, University of BernInstitute of Virology and Immunology, University of BernKU Leuven Department of Imaging and Pathology, Division of Translational Cell and Tissue ResearchInstitute of Virology and Immunology, University of BernKU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and ChemotherapyAbstract The SARS-CoV-2 main protease (3CLpro) is one of the promising therapeutic targets for the treatment of COVID-19. Nirmatrelvir is the first 3CLpro inhibitor authorized for treatment of COVID-19 patients at high risk of hospitalization. We recently reported on the in vitro selection of SARS-CoV-2 3CLpro resistant virus (L50F-E166A-L167F; 3CLprores) that is cross-resistant with nirmatrelvir and other 3CLpro inhibitors. Here, we demonstrate that the 3CLprores virus replicates efficiently in the lungs of intranasally infected female Syrian hamsters and causes lung pathology comparable to that caused by the WT virus. Moreover, hamsters infected with 3CLprores virus transmit the virus efficiently to co-housed non-infected contact hamsters. Importantly, at a dose of 200 mg/kg (BID) of nirmatrelvir, the compound was still able to reduce the lung infectious virus titers of 3CLprores-infected hamsters by 1.4 log10 with a modest improvement in the lung histopathology as compared to the vehicle control. Fortunately, resistance to Nirmatrelvir does not readily develop in clinical setting. Yet, as we demonstrate, in case drug-resistant viruses emerge, they may spread easily which may thus impact therapeutic options. Therefore, the use of 3CLpro inhibitors in combination with other drugs may be considered, especially in immunodeficient patients, to avoid the development of drug-resistant viruses.https://doi.org/10.1038/s41467-023-37773-6 |
| spellingShingle | Rana Abdelnabi Dirk Jochmans Kim Donckers Bettina Trüeb Nadine Ebert Birgit Weynand Volker Thiel Johan Neyts Nirmatrelvir-resistant SARS-CoV-2 is efficiently transmitted in female Syrian hamsters and retains partial susceptibility to treatment Nature Communications |
| title | Nirmatrelvir-resistant SARS-CoV-2 is efficiently transmitted in female Syrian hamsters and retains partial susceptibility to treatment |
| title_full | Nirmatrelvir-resistant SARS-CoV-2 is efficiently transmitted in female Syrian hamsters and retains partial susceptibility to treatment |
| title_fullStr | Nirmatrelvir-resistant SARS-CoV-2 is efficiently transmitted in female Syrian hamsters and retains partial susceptibility to treatment |
| title_full_unstemmed | Nirmatrelvir-resistant SARS-CoV-2 is efficiently transmitted in female Syrian hamsters and retains partial susceptibility to treatment |
| title_short | Nirmatrelvir-resistant SARS-CoV-2 is efficiently transmitted in female Syrian hamsters and retains partial susceptibility to treatment |
| title_sort | nirmatrelvir resistant sars cov 2 is efficiently transmitted in female syrian hamsters and retains partial susceptibility to treatment |
| url | https://doi.org/10.1038/s41467-023-37773-6 |
| work_keys_str_mv | AT ranaabdelnabi nirmatrelvirresistantsarscov2isefficientlytransmittedinfemalesyrianhamstersandretainspartialsusceptibilitytotreatment AT dirkjochmans nirmatrelvirresistantsarscov2isefficientlytransmittedinfemalesyrianhamstersandretainspartialsusceptibilitytotreatment AT kimdonckers nirmatrelvirresistantsarscov2isefficientlytransmittedinfemalesyrianhamstersandretainspartialsusceptibilitytotreatment AT bettinatrueb nirmatrelvirresistantsarscov2isefficientlytransmittedinfemalesyrianhamstersandretainspartialsusceptibilitytotreatment AT nadineebert nirmatrelvirresistantsarscov2isefficientlytransmittedinfemalesyrianhamstersandretainspartialsusceptibilitytotreatment AT birgitweynand nirmatrelvirresistantsarscov2isefficientlytransmittedinfemalesyrianhamstersandretainspartialsusceptibilitytotreatment AT volkerthiel nirmatrelvirresistantsarscov2isefficientlytransmittedinfemalesyrianhamstersandretainspartialsusceptibilitytotreatment AT johanneyts nirmatrelvirresistantsarscov2isefficientlytransmittedinfemalesyrianhamstersandretainspartialsusceptibilitytotreatment |